$AURA

Gibney Anthony S sold $82K of AURA

Gibney Anthony S (See Remarks) sold 12,824 shares of Aura Biosciences, Inc. (AURA) at $6.42 on 2026-06-16.

Original reporting
SEC EDGAR · Gibney Anthony S
Published Jun 16, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AURA
Neutral
medium confidence
Mentioned
$AURA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AURANeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (shares, price, total value, post-transaction holdings). This can slightly influence sentiment but does not change the company’s fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new guidance, trial, deal, or regulatory event in the text.

03

What to watch

Form 4 sales often have limited interpretive value unless paired with large size, repeated selling, or concurrent negative company disclosures (none provided here).

Relevance 3/10Novelty 5/10Timing: Filed same day (2026-06-16) for an officer sale

Background

The article is an SEC Form 4 insider transaction disclosure for Aura Biosciences.

Company-level read

Ticker impact

$AURANeutralMedium confidence
Context

Aura Biosciences disclosed an officer open-market sale of 12,824 shares at $6.42 on 2026-06-16 via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 sale with no 10b5-1 plan stated and no accompanying operational/regulatory update.

Market effects

Minimal; this is company-specific insider activity without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or liquidity needs and does not necessarily reflect negative fundamentals, especially without a stated 10b5-1 plan.

Key entities

  • Aura Biosciences, Inc.

    Subject of the SEC Form 4 insider transaction; officer sold 12,824 shares at $6.42.

  • Gibney Anthony S

    Officer who reported the sale on 2026-06-16.

Related articles